Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

ry four weeks in the FOLPI regimen, was associated with less frequent and less severe neurotoxicity than the FOLFOX regimen where oxaliplatin has shown treatment-limiting neurotoxicity. These data support further development of picoplatin for this indication.

-- Presented expanded and updated results from our ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone in patients with HRPC at EORTC. Results showed that picoplatin can be safely administered with full-dose docetaxel, the standard of care for the first-line treatment of HRPC. Reductions of prostate specific antigen levels (PSA) of at least 50 percent were achieved in 78 percent of evaluable patients. This compared favorably to PSA response rates of approximately 45 percent with docetaxel alone and supports further development of picoplatin for this indication.

-- Announced this month that picoplatin was named by Windhover Information Inc. as one of the Top 10 most promising oncology projects in development that is available for partnering.

-- Made a presentation on the molecular mechanisms of platinum resistance and picoplatin in July at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium.

Corporate Developments

-- Secured a $27.6 million amended loan facility with GE Healthcare Financial Services and Silicon Valley Bank, a member company of SVB Financial Group, in September and exercised the option to draw down both tranches. The $27.6 million loan facility included the refinancing of the $7.6 million outstanding principal balance on our current loan facility. Cash and investment securities as of September 30, 2008, were $84.0 million and should fund operations into 2010.

-- Appointed Janet R. Rea, MSPH, RAC, as vice president, regulatory affairs and quality in July. Ms. Rea will execute regulatory and quality activities with the U.S. Food and Drug Administration and other regulatory authorities consistent
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 12, 2014 The ... Vascular Devices Market by Angioplasty Balloon ... (IVUS, OCT), IVC Filter (Retrievable), Endovascular ... analyzes and studies the major market ... U.S. and Canada. , Browse 108 ...
(Date:7/12/2014)... July 12, 2014 The Security Analytics ... 2013 to $3,376.6 million by 2019, at an expected ... 2019. The challenges to counter the increasing number of ... of outdated cyber defense systems in organizations are enormous. ... and remodeling their existing architecture to develop better and ...
(Date:7/12/2014)... 2014 Casinos in Australia ... competition from international and online casinos. Revenue is estimated ... five years through 2014-15. Greater per capita gambling expenditure ... services. Rises in discretionary income levels have also assisted ... non-essential items such as casino gambling services. Revenue is ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 "The second ... it’s uncomfortable and painful to wear shoes," said an inventor ... special sock that prevents this from happening. , He then ... effective way to prevent the second and big toes from ... endurance while wearing shoes. Ergonomic and easy to use, it's ...
(Date:7/12/2014)... Using and carrying around a catheter bag ... Ashland, Va., decided that there needed to be an ... conceive of our design," he said. , They then ... provides an inconspicuous way to use and carry a ... promotes comfort and peace of mind. Producible in design ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Casinos in Australia Industry Market Research Report Now Updated by IBISWorld 4
... researchers at the University of Cincinnati (UC) have found ... therapeutic treatments for obesity-related disorders, like diabetes and heart ... American Heart Association,s Scientific Session in Chicago Nov. 16. ... of cardiovascular diseases found that action by the enzyme ...
... Amanda Gardner HealthDay Reporter , TUESDAY, Nov. ... clogged arteries in addition to standard drug therapy seems ... diabetics with heart disease, new research finds. The ... annual meeting in Chicago, is part of a larger ...
... , TUESDAY, Nov. 16 (HealthDay News) -- Men who ... disease, new research suggests. The notion is based on ... a thickening of the men,s neck,s carotid artery wall. Such ... for heart disease. What,s more, the link between sleep ...
... HealthDay Reporter , TUESDAY, Nov. 16 (HealthDay News) ... were retracted by medical journals for serious errors or faked ... U.S. researchers. In fact, U.S. scientists were responsible for ... errors, as well as for 84 of the papers retracted ...
... Three-year-old Denver resident Brianna,s favorite color was yellow and her ... At 18 months she strapped on her first pair of ... loved playing with her brother and noticed everything. ... from a cardiac arrhythmia known as Long QT Syndrome. Brianna,s ...
... 16 (HealthDay News) -- New animal research has identified a ... so-called "good" cholesterol, at least in mice. Working with ... in question -- labeled "miR-33a" -- helps to regulate cholesterol ... genes. Specifically, the sequence was found to inhibit production ...
Cached Medicine News:Health News:Enzyme action could be target for diabetes, heart disease treatments 2Health News:Enzyme action could be target for diabetes, heart disease treatments 3Health News:Adding Surgery to Meds May Help Diabetics With Heart Disease 2Health News:Shorter Sleep in Men Ups Risk of Heart Disease: Study 2Health News:U.S. Scientists Commit Most Research Fraud: Study 2Health News:U.S. Scientists Commit Most Research Fraud: Study 3Health News:University of Colorado in pilot project to map defibrillators 2Health News:Scientists Find Way to Boost 'Good' Cholesterol in Mice 2
(Date:7/10/2014)... 10, 2014  The U.S. Department of Health and ... University Hospitals (UH) Case Medical Center Seidman Cancer Center ... aimed at improving care for patients with complex cancer. ... will test a unique model developed at UH to ... significant comorbidities, or demonstrated need for high health care ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
... Greenville, SC, announced today that its Glucommander™ 2.0 Enterprise software ... 2 - 17. Glytec,s Glucommander was the first insulin dosing ... it is the only company to achieve specific ... company cleared to offer this technology to hospitals caring for ...
... OLATHE, Kan., May 21, 2012  BD (Becton, Dickinson and ... medical technology company, and Heart to Heart International, a ... their second joint volunteer initiative to strengthen healthcare in ... the world will build upon the progress made by ...
Cached Medicine Technology:Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 3
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
... The CSV-1000RS test face is used ... test presents ETDRS LogMAR acuity from 20/10 ... frequency at 12 cycles/degree. , ,The patient ... chair for ETDRS acuity and contrast sensitivity. ...
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
Medicine Products: